Lichty BD - Search Results

1

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA. Pol JG, et al. Among authors: lichty bd. Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019. Oncoimmunology. 2018. PMID: 30546947 Free PMC article.

2

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Stojdl DF, et al. Nat Med. 2000 Jul;6(7):821-5. doi: 10.1038/77558. Nat Med. 2000. PMID: 10888934

3

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC. Stojdl DF, et al. Among authors: lichty bd. J Virol. 2000 Oct;74(20):9580-5. doi: 10.1128/jvi.74.20.9580-9585.2000. J Virol. 2000. PMID: 11000229 Free PMC article.

4

Oncolytic viruses: programmable tumour hunters.

Bell JC, Garson KA, Lichty BD, Stojdl DF. Bell JC, et al. Among authors: lichty bd. Curr Gene Ther. 2002 May;2(2):243-54. doi: 10.2174/1566523024605582. Curr Gene Ther. 2002. PMID: 12109220 Review.

5

Getting oncolytic virus therapies off the ground.

Bell JC, Lichty B, Stojdl D. Bell JC, et al. Cancer Cell. 2003 Jul;4(1):7-11. doi: 10.1016/s1535-6108(03)00170-3. Cancer Cell. 2003. PMID: 12892708 Free article.

6

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Stojdl DF, et al. Among authors: lichty bd. Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1. Cancer Cell. 2003. PMID: 14585354 Free article.

7

Vesicular stomatitis virus: re-inventing the bullet.

Lichty BD, Power AT, Stojdl DF, Bell JC. Lichty BD, et al. Trends Mol Med. 2004 May;10(5):210-6. doi: 10.1016/j.molmed.2004.03.003. Trends Mol Med. 2004. PMID: 15121047 Review.

8

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC. Lichty BD, et al. Hum Gene Ther. 2004 Sep;15(9):821-31. doi: 10.1089/hum.2004.15.821. Hum Gene Ther. 2004. PMID: 15353037

9

Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif.

Lichty BD, McBride H, Hanson S, Bell JC. Lichty BD, et al. J Gen Virol. 2006 Nov;87(Pt 11):3379-3384. doi: 10.1099/vir.0.81762-0. J Gen Virol. 2006. PMID: 17030873

10

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Power AT, et al. Among authors: lichty bd. Mol Ther. 2007 Jan;15(1):123-30. doi: 10.1038/sj.mt.6300039. Mol Ther. 2007. PMID: 17164783 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page